A DNA-binding mutant of TAL1 cooperates with LMO2 to cause T cell leukemia in mice

Oncogene

Volumn 30, Issue 10, 2011, Pages 1252-1260

  Draheim, K M ^a   Hermance, N ^a   Yang, Y ^a   Arous, E ^a   Calvo, J ^b   Kelliher, M A ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b Massachusetts Institute of Technology Cambridge   (United States)

Author keywords

E47; HEB; Lmo2; T cell acute lymphoblastic leukemia (T ALL); TAL1

Indexed keywords

CD4 ANTIGEN; LIM PROTEIN; PROTEIN LMO2; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIGEN EXPRESSION; ARTICLE; BINDING AFFINITY; CELL MATURATION; DNA BINDING; ERYTHROPOIESIS; GENE EXPRESSION; GENE INSERTION; GENE LOCUS; GENETIC TRANSCRIPTION; IMMUNOPHENOTYPING; MOUSE; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; T CELL LEUKEMIA; TAL1 ONCOGENE; THYMOCYTE;

ANIMALS; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; BLOTTING, SOUTHERN; CELL DIFFERENTIATION; CELL SEPARATION; CHROMATIN IMMUNOPRECIPITATION; DNA-BINDING PROTEINS; FLOW CYTOMETRY; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; LEUKEMIA, T-CELL; METALLOPROTEINS; MICE; MICE, TRANSGENIC; MUTATION; PROTO-ONCOGENE PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; T-LYMPHOCYTES; TRANSCRIPTION FACTOR 3;

MUS; MUS MUSCULUS;

EID: 79952532337     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2010.495     Document Type: Article

References (44)

1. Abraham N, Miceli MC, Parnes JR, Veillette A. (1991). Enhancement of T-cell responsiveness by the lymphocyte-specific tyrosine protein kinase p56lck. Nature 350: 62-66. (Pubitemid 21926121)
2. Aoyama M, Ozaki T, Inuzuka H, Tomotsune D, Hirato J, Okamoto Y et al. (2005). LMO3 interacts with neuronal transcription factor, HEN2, and acts as an oncogene in neuroblastoma. Cancer Res 65: 4587-4597. (Pubitemid 40740794)
3. Aplan PD, Jones CA, Chervinsky DS, Zhao X, Ellsworth M, Wu C et al. (1997). An scl gene product lacking the transactivation domain induces bony abnormalities and cooperates with LMO1 to generate T-cell malignancies in transgenic mice. Embo J 16: 2408-2419. (Pubitemid 27258639)
4. Bain G, Engel I, Robanus Maandag EC, te Riele HP, Voland JR, Sharp LL et al. (1997). E2A deficiency leads to abnormalities in alphabeta T-cell development and to rapid development of T-cell lymphomas. Mol Cell Biol 17: 4782-4791. (Pubitemid 27318153)
5. Berg T, Cohen SB, Desharnais J, Sonderegger C, Maslyar DJ, Goldberg J et al. (2002). Small-molecule antagonists of Myc/Max dimerization inhibit Myc-induced transformation of chicken embryo fibroblasts. Proc Natl Acad Sci USA 99: 3830-3835. (Pubitemid 34252191)
6. Boehm T, Foroni L, Kennedy M, Rabbitts TH. (1990). The rhombotin gene belongs to a class of transcriptional regulators with a potential novel protein dimerisation motif. Oncogene 5: 1103-1105.
7. Clackson T, Wells JA. (1995). A hot spot of binding energy in a hormone-receptor interface. Science 267: 383-386.
8. Davenport J, Neale GA, Goorha R. (2000). Identification of genes potentially involved in LMO2-induced leukemogenesis. Leukemia 14: 1986-1996.
9. Ferrando AA, Neuberg DS, Staunton J, Loh ML, Huard C, Raimondi SC et al. (2002). Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia. Cancer Cell 1: 75-87. (Pubitemid 41039178)
10. Fisch P, Boehm T, Lavenir I, Larson T, Arno J, Forster A et al. (1992). T-cell acute lymphoblastic lymphoma induced in transgenic mice by the RBTN1 and RBTN2 LIM-domain genes. Oncogene 7: 2389-2397.
11. Garcia IS, Kaneko Y, Gonzalez-Sarmiento R, Campbell K, White L, Boehm T et al. (1991). A study of chromosome 11p13 translocations involving TCR beta and TCR delta in human T cell leukaemia. Oncogene 6: 577-582. (Pubitemid 21924121)
12. Goardon N, Lambert JA, Rodriguez P, Nissaire P, Herblot S, Thibault P et al. (2006). ETO2 coordinates cellular proliferation and differentiation during erythropoiesis. Embo J 25: 357-366. (Pubitemid 43152856)
13. Greenbaum S, Zhuang Y. (2002). Regulation of early lymphocyte development by E2A family proteins. Semin Immunol 14: 405-414.
14. Hacein-Bey-Abina S, Garrigue A, Wang GP, Soulier J, Lim A, Morillon E et al. (2008). Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J Clin Invest 118: 3132-3142.
15. Hacein-Bey-Abina S, von Kalle C, Schmidt M, Le Deist F, Wulffraat N, McIntyre E et al. (2003a). A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 348: 255-256. (Pubitemid 36077924)
16. Hacein-Bey-Abina S, Von Kalle C, Schmidt M, McCormack MP, Wulffraat N, Leboulch P et al. (2003b). LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 302: 415-419. (Pubitemid 37296260)
17. Herblot S, Steff AM, Hugo P, Aplan PD, Hoang T. (2000). SCL and LMO1 alter thymocyte differentiation: inhibition of E2A-HEB function and pre-T alpha chain expression. Nat Immunol 1: 138-144.
18. Howe SJ, Mansour MR, Schwarzwaelder K, Bartholomae C, Hubank M, Kempski H et al. (2008). Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. J Clin Invest 118: 3143-3150.
19. Hsu HL, Wadman I, Tsan JT, Baer R. (1994). Positive and negative transcriptional control by the TAL1 helix-loop-helix protein. Proc Natl Acad Sci USA 91: 5947-5951.
20. Hsu LY, Lauring J, Liang HE, Greenbaum S, Cado D, Zhuang Y et al. (2003). A conserved transcriptional enhancer regulates RAG gene expression in developing B cells. Immunity 19: 105-117. (Pubitemid 36859905)
21. Huang EY, Gallegos AM, Richards SM, Lehar SM, Bevan MJ. (2003). Surface expression of Notch1 on thymocytes: correlation with the double-negative to double-positive transition. J Immunol 171: 2296-2304. (Pubitemid 37025534)
22. Huang S, Brandt SJ. (2000). mSin3A regulates murine erythroleuke-mia cell differentiation through association with the TAL1 (or SCL) transcription factor. Mol Cell Biol 20: 2248-2259. (Pubitemid 30123840)
23. Kelliher MA, Seldin DC, Leder P. (1996). Tal-1 induces T cell acute lymphoblastic leukemia accelerated by casein kinase IIalpha. Embo J 15: 5160-5166. (Pubitemid 26336198)
24. Krosl G, He G, Lefrancois M, Charron F, Romeo PH, Jolicoeur P et al. (1998). Transcription factor SCL is required for c-kit expression and c-Kit function in hemopoietic cells. J Exp Med 188: 439-450. (Pubitemid 28369134)
25. Kussie PH, Gorina S, Marechal V, Elenbaas B, Moreau J, Levine AJ et al. (1996). Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science 274: 948-953. (Pubitemid 26398409)
26. Lahlil R, Lecuyer E, Herblot S, Hoang T. (2004). SCL assembles a multifactorial complex that determines glycophorin A expression. Mol Cell Biol 24: 1439-1452. (Pubitemid 38167068)
27. Larson RC, Lavenir I, Larson TA, Baer R, Warren AJ, Wadman I et al. (1996). Protein dimerization between Lmo2 (Rbtn2) and Tal1 alters thymocyte development and potentiates T cell tumorigenesis in transgenic mice. Embo J 15: 1021-1027. (Pubitemid 26077830)
28. Lecuyer E, Herblot S, Saint-Denis M, Martin R, Begley CG, Porcher C et al. (2002). The SCL complex regulates c-kit expression in hematopoietic cells through functional interaction with Sp1. Blood 100: 2430-2440.
29. Nam CH, Lobato MN, Appert A, Drynan LF, Tanaka T, Rabbitts TH. (2008). An antibody inhibitor of the LMO2-protein complex blocks its normal and tumorigenic functions. Oncogene 27: 4962-4968.
30. O'Neil J, Billa M, Oikemus S, Kelliher M. (2001). The DNA binding activity of TAL-1 is not required to induce leukemia/lymphoma in mice. Oncogene 20: 3897-3905. (Pubitemid 32646200)
31. O'Neil J, Shank J, Cusson N, Murre C, Kelliher M. (2004). TAL1/SCL induces leukemia by inhibiting the transcriptional activity of E47/ HEB. Cancer Cell 5: 587-596. (Pubitemid 38748920)
32. Ono Y, Fukuhara N, Yoshie O. (1997). Transcriptional activity of TAL1 in T cell acute lymphoblastic leukemia (T-ALL) requires RBTN1 or -2 and induces TALLA1, a highly specific tumor marker of T-ALL. J Biol Chem 272: 4576-4581. (Pubitemid 27078539)
33. Rabbitts TH. (1994). Chromosomal translocations in human cancer. Nature 372: 143-149. (Pubitemid 24347832)
34. Ryan DP, Duncan JL, Lee C, Kuchel PW, Matthews JM. (2008). Assembly of the oncogenic DNA-binding complex LMO2-Ldb1-TAL1-E12. Proteins 70: 1461-1474. (Pubitemid 351304104)
35. Schlaeger TM, Schuh A, Flitter S, Fisher A, Mikkola H, Orkin SH et al. (2004). Decoding hematopoietic specificity in the helix-loop-helix domain of the transcription factor SCL/Tal-1. Mol Cell Biol 24: 7491-7502. (Pubitemid 39121477)
36. Sharma VM, Calvo JA, Draheim KM, Cunningham LA, Hermance N, Beverly L et al. (2006). Notch1 contributes to mouse T-cell leukemia by directly inducing the expression of c-myc. Mol Cell Biol 26: 8022-8031. (Pubitemid 44631001)
37. Valge-Archer VE, Osada H, Warren AJ, Forster A, Li J, Baer R et al. (1994). The LIM protein RBTN2 and the basic helix-loop-helix protein TAL1 are present in a complex in erythroid cells. Proc Natl Acad Sci USA 91: 8617-8621.
38. Visvader JE, Venter D, Hahm K, Santamaria M, Sum EY, O'Reilly L et al. (2001). The LIM domain gene LMO4 inhibits differentiation of mammary epithelial cells in vitro and is overexpressed in breast cancer. Proc Natl Acad Sci USA 98: 14452-14457. (Pubitemid 33121412)
39. Wadman I, Li J, Bash RO, Forster A, Osada H, Rabbitts TH et al. (1994). Specific in vivo association between the bHLH and LIM proteins implicated in human T cell leukemia. Embo J 13: 4831-4839. (Pubitemid 24319365)
40. Wadman IA, Osada H, Grutz GG, Agulnick AD, Westphal H, Forster A et al. (1997). The LIM-only protein Lmo2 is a bridging molecule assembling an erythroid, DNA-binding complex which includes the TAL1, E47, GATA-1 and Ldb1/NLI proteins. Embo J 16: 3145-3157. (Pubitemid 27234954)
41. Wells JA. (1996). Binding in the growth hormone receptor complex. Proc Natl Acad Sci USA 93: 1-6. (Pubitemid 26038094)
42. Wells JA, de Vos AM. (1996). Hematopoietic receptor complexes. Annu Rev Biochem 65: 609-634. (Pubitemid 26250621)
43. Xu Z, Huang S, Chang LS, Agulnick AD, Brandt SJ. (2003). Identification of a TAL1 target gene reveals a positive role for the LIM domain-binding protein Ldb1 in erythroid gene expression and differentiation. Mol Cell Biol 23: 7585-7599. (Pubitemid 37271458)
44. Yan W, Young AZ, Soares VC, Kelley R, Benezra R, Zhuang Y. (1997). High incidence of T-cell tumors in E2A-null mice and E2A/ Id1 double-knockout mice. Mol Cell Biol 17: 7317-7327. (Pubitemid 27505961)